|
Intravesical rad-IFNα/Syn3 for patients with high-grade, bacillus Calmette-Guérin (BCG) refractory or relapsed non-muscle invasive bladder cancer: A phase II randomized study. |
|
|
Consulting or Advisory Role - Astellas Medivation |
|
|
Consulting or Advisory Role - Bayer; Dendreon; Ferring; Janssen Scientific Affairs; Medivation/Astellas; Sanofi; Takeda; Tolmar |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Swan Valley Medical |
Honoraria - Astellas Pharma; Bayer; Dendreon; Janssen; Medivation/Astellas |
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon; Janssen; Medivation/Astellas |
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Dendreon; Janssen; Medivation |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Janssen (Inst); Medivation/Astellas (Inst); Spectrum Pharmaceuticals |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; dendreon; Janssen; Medivation/Astellas; Spectrum Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
Research Funding - FKD Therapies |
|
|
|
Consulting or Advisory Role - Abbott Molecular; Heat Biologics; Merck; Photocure; Sanofi; Spectrum Pharmaceuticals; Telesta Therapeutics; Theralase |
Research Funding - FKD Therapies; Heat Biologics; Merck; Photocure |
|
|
Consulting or Advisory Role - Augmenix; BioCancell; MDxhealth; Physical Optics Corporation; SonaCare Medical |
Research Funding - Abbott Molecular; Cepheid; Danone; Metabolon; pacific edge |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - BioCancell; Ferring; UroGen pharma; Vaxiion |
Other Relationship - Endo Pharmaceuticals; Roche/Genentech; Viventia Biotech |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Combat Medical; Taris |
Other Relationship - Abbott; Dendreon; GlaxoSmithKline; Roche/Genentech |
|
|
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); BIND Therapeutics (Inst); Cerulean Pharma (Inst); Dendreon (Inst); Exelixis (Inst); Johnson & Johnson (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tokai Pharmaceuticals (Inst) |
|
|
Leadership - FKD Therapies |
Travel, Accommodations, Expenses - FKD Therapies |
|
|
Leadership - FKD Therapies |
Consulting or Advisory Role - FKD Therapies |
Travel, Accommodations, Expenses - FKD Therapies |
|
|
No Relationships to Disclose |